TY - JOUR
T1 - Implications of mutation profiling in myeloid malignancies
T2 - Part 1: Myelodysplastic syndromes and acute myeloid leukemia
AU - Tremblay, Douglas
AU - Sokol, Kelsey
AU - Bhalla, Sheena
AU - Rampal, Raajit
AU - Mascarenhas, John O.
N1 - Publisher Copyright:
© 2018, UBM Medica Healthcare Publications. All rights reserved.
PY - 2018
Y1 - 2018
N2 - The advent of high-throughput gene sequencing has revolutionized our understanding of the genetic mutations that drive myeloid malignancies. While these mutations are of interest pathobiologically, they are increasingly being recognized as clinically meaningful in providing diagnostic, prognostic, and therapeutic information to guide patient care. In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies. Next, we discuss the diagnostic and prognostic role of mutation profiling in myelodysplastic syndrome and acute myeloid leukemia. Finally, we detail the therapeutic implications of specific mutations in myelodysplastic syndrome and acute myeloid leukemia. In Part 2, we will discuss similar clinical approaches using mutation profiling in myeloproliferative neoplasms and other myeloid malignancies.
AB - The advent of high-throughput gene sequencing has revolutionized our understanding of the genetic mutations that drive myeloid malignancies. While these mutations are of interest pathobiologically, they are increasingly being recognized as clinically meaningful in providing diagnostic, prognostic, and therapeutic information to guide patient care. In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies. Next, we discuss the diagnostic and prognostic role of mutation profiling in myelodysplastic syndrome and acute myeloid leukemia. Finally, we detail the therapeutic implications of specific mutations in myelodysplastic syndrome and acute myeloid leukemia. In Part 2, we will discuss similar clinical approaches using mutation profiling in myeloproliferative neoplasms and other myeloid malignancies.
UR - http://www.scopus.com/inward/record.url?scp=85050429419&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050429419&partnerID=8YFLogxK
M3 - Article
C2 - 29684235
AN - SCOPUS:85050429419
SN - 0890-9091
VL - 32
SP - e38-e44
JO - ONCOLOGY (United States)
JF - ONCOLOGY (United States)
IS - 4
ER -